About the Program

The NewYork-Presbyterian/Weill Cornell Transplant program, in cooperation with the Rogosin Institute, was the first kidney transplant program established in New York State, now more than six decades ago.  Since that time, over 7,500 kidney transplants have been performed. With approximately 200 kidney transplants performed each year since 2006, our program is among the largest in the country offering the very latest transplant management protocols and surgical interventions.

Our transplant center’s patient and graft survival rates are excellent, which is especially notable given our diverse and often complicated patient population. Transplant outcomes are calculated by the Scientific Registry of Transplant Recipients (SRTR) based on the mix of recipient and donor characteristics at our center compared with experience with similar patients throughout the country.

Our kidney transplant program is a proud participant in the Increasing Organ Transplant Access (IOTA) Model, a program developed by the Centers for Medicare and Medicaid Services (CMS). The IOTA Model aims to increase access to life-saving kidney transplants for patients living with end-stage renal disease (ESRD) by incentivizing kidney transplant hospitals to improve their care delivery capabilities and efficiency, as well as supporting greater care coordination and person-centeredness in the organ transplant waitlist process.  Click here to learn more about the IOTA Model.

Molecular tools developed at Weill Cornell Medicine allow us, for the first time in the history of kidney transplantation, to individualize the medication regimen used to suppress the immune system. At the same time, these tools reduce the amount of exposure to these medications.

Since 2001, approximately 75 percent of our kidney transplant patients have received a steroid-sparing medication regimen and over 2,500 transplanted patients are completely off of steroids.